Confluence Discovery Technologies

Confluence Discovery Technologies is a Boulder-based, privately held contract research organization (CRO) founded in 2018 and operating as a wholly-owned subsidiary of Aclaris Therapeutics. The company provides integrated, expert-driven drug discovery services, leveraging deep scientific specialization in areas like mechanistic enzymology, immuno-oncology, and biomarker development to help clients accelerate their research timelines from idea to IND. Its business model is based on offering tailored, 'plug-and-play' scientific solutions and full-service project management to external biopharma partners, positioning it as a revenue-generating service provider within the broader drug discovery ecosystem.

Integrated suite of expert-driven scientific services and assay platforms in mechanistic enzymology, immuno-oncology, and biomarker development, emphasizing deep kinetic analysis and cross-platform integration.

Confluence competes in the fragmented drug discovery CRO market against large players (e.g., Charles River, Eurofins) offering broad capabilities and smaller niche labs. Its differentiation is a hybrid model: deep, PhD-level scientific expertise akin to a boutique consultancy, combined with full-service project execution typically offered by larger CROs.